ReviewCurrent allergy and asthma reports2008
Immunomodulatory approaches to the management of chronic urticaria: an immune-mediated inflammatory disease.
Review in Current allergy and asthma reports, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- Immune cells influence chronic spontaneous urticaria by inflammatory proteins: Mendelian randomization and bioinformatic analysis.The journal of allergy and clinical immunology. Global · 2026Article
- Article
- Burden of and Trends in Urticaria Globally, Regionally, and Nationally from 1990 to 2019: Systematic Analysis.JMIR public health and surveillance · 2023Article
- Exacerbation of Chronic Spontaneous Urticaria Symptoms in COVID-19 Patients, Case Report.BioNanoScience · 2022Article
- Changing Assessment of Diet in Chronic Spontaneous Urticaria.Acta dermato-venereologica · 2020Article
- OSMR gene effect on the pathogenesis of chronic autoimmune Urticaria via the JAK/STAT3 pathway.Molecular medicine (Cambridge, Mass.) · 2018Article
- Mediators of Inflammation and Angiogenesis in Chronic Spontaneous Urticaria: Are They Potential Biomarkers of the Disease?Mediators of inflammation · 2017Review
- Looking forward to new targeted treatments for chronic spontaneous urticaria.Clinical and translational allergy · 2017Review
- Leukotriene receptor antagonists in monotherapy or in combination with antihistamines in the treatment of chronic urticaria: a systematic review.Journal of asthma and allergy · 2008Article
- New concepts in chronic urticaria.Current opinion in immunology · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although commonly encountered in clinical practice, chronic urticaria (CU) remains difficult to treat. In contrast to acute urticaria, neither exogenous triggers nor specific immunoglobulin E are identified in most chronic cases. A body of evidence suggests that CU is represented within the spectrum of immune-mediated inflammatory diseases (IMID). Our understanding of the CU disease pathogenesis now recognizes a role for T cells, B cells, and autoantibodies, and intrinsic abnormalities of histamine-releasing effector cells, thus providing new targets of intervention beyond the current mainstay of often inadequate symptomatic treatment directed against histamine receptors and steroids, with their attendant morbidities. Agents previously used to treat other autoimmune and inflammatory diseases have demonstrated efficacy in CU. Newer biologic and nonbiologic immunomodulatory agents approved for other indications and in clinical development provide potential options for this often severe disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.